Non-Viral Gene Therapies Get €51M Boost, Though Challenges Remain
Although most gene therapy still relies on non-infectious viral vectors for delivery, a recent venture…
Although most gene therapy still relies on non-infectious viral vectors for delivery, a recent venture…
From red blood cells to platelets, the cells in our own blood could prove an…
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled…
Update (29/06/2020): Hyloris Pharmaceuticals’ Euronext IPO -- one of only a handful of biotech and…
British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US…
Any compounds you use during drug discovery and development have started their journey long before…
DelSiTech is a Finnish company developing injectable silica gel implants that release drugs slowly over…
By the year 2022, half of the top 100 drug sales will be biologics. And…
Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed,…
Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a…
The discovery and subsequent development of more effective and safer new medicines remains a key…
Santa Claus is not the only busy one in the weeks leading up to Christmas…